Background
==========

Recent advances in genome-wide molecular cytogenetics allow the identification of novel molecular abnormalities \[[@B1]-[@B8]\]. Emerging data demonstrate that myelodysplastic syndrome (MDS) exhibits abundant CNAs and cnLOH, often in the setting of a normal karyotype \[[@B9]-[@B11]\]. Loss of heterozygosity (LOH) is an indicator of neoplastic evolution and disease progression \[[@B12],[@B13]\]. Copy-neutral LOH (cnLOH) arises either via a hemizygous deletion in one homolog and duplication of the other, or uniparental disomy (UPD). Both types of somatic LOH have been observed in studies of various cancer types and may explain some of the mechanisms by which tumor suppressor genes (TSGs) are inactivated or activating mutations in oncogenes are duplicated. Acquired UPD (aUPD) is now understood to be common in oncogenesis and appears to be a mechanism to increase the allelic burden of the mutated genes \[[@B14]-[@B24]\]. Thus, it is important to know the regions of cnLOH to determine new regions containing potential mutational targets affecting disease pathogenesis and treatment outcome \[[@B25],[@B26]\].

Application of SNP-array technology has led to the identification of recurrent regions of cnLOH in a majority of the chromosomes \[[@B4],[@B13],[@B25],[@B27]-[@B30]\] and recurrent pathogenic mutations. These findings have greatly advanced our understanding of the molecular mechanisms of cancer evolution and have led to the development of therapeutics and diagnostic tests. In this respect, mutation analysis helps further stratify neoplasms and their treatment outcome \[[@B31]-[@B34]\].

In this study, we used SNP array-based genomic profiling to detect acquired copy number alterations (aCNA) and cnLOHs, together with sequence analysis of genes commonly mutated in MDS, in a patient with normal chromosome and MDS FISH (fluorescence in situ hybridization) panel results.

Clinical presentation
=====================

Morphologic and immunophenotypic findings
-----------------------------------------

An 88-year-old woman presented with leukocytosis (16.2×10^9^/L) including minimal monocytosis (1.0×10^9^/L), mild anemia (HGB 105 g/L), and moderate thrombocytopenia (79×10^9^/L). Bone marrow morphologic and flow cytometric examinations revealed hypercellular bone marrow with granulocytic predominance with left-shifted and unusual maturation, and occasional atypical granulocytes and megakaryocytes, but no significant increase in monocytes or myeloblasts (Figure [1](#F1){ref-type="fig"}). A myeloid neoplasm positive for CD13 and CD33 was diagnosed, best classified as MDS, refractory cytopenia with multilineage dysplasia. Data on therapeutic interventions were not available for this study. At the 5-month follow-up, the overall morphologic and immunophenotypic findings were similar to those at initial presentation.

![**Morphologic and immunophenotypic findings. A)** At presentation, there was granulocytic predominance with progressive maturation and no significant increase in blasts or monocytes. The core biopsy shows hypercellular bone marrow with left-shifted granulocytic predominance. Flow cytometry reveals granulocytic predominance (in green) but no significant increase in monocytes (in blue) or myeloblasts (in red). **B)** At follow-up, the morphologic and immunophenotypic findings are similar to those at presentation.](1755-8166-7-35-1){#F1}

Chromosome and FISH study
-------------------------

Bone marrow cells were cultivated for 24 and 48 hours in RPMI 1640 or Marrow Max Medium with 10% fetal calf serum (Life Technologies, Grand Island, NY 14072, USA). In total, 20 mitoses were analyzed according to the ISCN (International System for Human Cytogenetic Nomenclature), with a resolution of 300 bands per haploid karyotype. FISH analyses using a panel of MDS probes (-5/5q-, -7/7q-, +8 and 20q-; Vysis, Downers Grove, IL, USA) and BlueGnome probes RP11-114B12 (Illumina, San Diego, CA, USA) for the deleted region 5q31.2 were performed on interphase cells according to the manufacturer's protocol. Subsequently, 200 cells were examined carefully.

Oligo SNP array
---------------

Microdeletion/microduplication screening was performed using an SNP-array platform (CytoScan HD SNP array; Affymetrix, Santa Clara, CA), following the manufacturer's instructions. The CytoScan HD array has 2.67 million probes, including 1.9 million copy number probes and 0.75 million SNP probes. Array data were analyzed using the Chromosome Analysis Suite (ChAS) software v 2.0 (Affymetrix).

Mutation analysis
-----------------

Genomic DNA was also tested for mutations in 19 genes that are recurrently mutated in myeloid neoplasms, including ASXL1, EZH2, RUNX1, IDH1, IDH2, KRAS, NRAS and TET2. Sequencing was performed using a TruSeq custom amplicon assay on the MiSeq sequencing platform (Illumina, Hayward, CA). Analysis was performed using SeqPilot software (JSI Medical Systems, Costa Mesa, CA). The assay had sufficient read depth to provide a minimum sensitivity of 5% to 10% for mutation detection.

Results and discussion
======================

During the initial evaluation of the patient, cytogenetic analysis revealed a normal karyotype and FISH studies were negative for aCNAs commonly seen in MDS (MDS panel) (Figure [2](#F2){ref-type="fig"}A-D). Microarray analysis revealed a microdeletion of approximately 896 kb at the 5q31.2 chromosomal region and three segments of somatic cnLOH for the entire long arm of chromosome 4 (136 Mb), the distal half of the long arm of chromosome 7 (50 Mb), and the entire chromosome 22 (31 Mb). The microdeletion at 5q31.2 extended from 137,821,899 to 138,718,504 bp (UCSC genome Browser; <http://genome.ucsc.edu/>; hg19 release) and included the *ETF1, HSPA9, SNORD63, CTNNA1, LRRTM2, SIL1, SNHG4, MATR3, SNORA74A, PAIP2*, and *SLC23A1* genes (Figure [3](#F3){ref-type="fig"}).

![**Routine cytogenetic and fluorescence insitu hybridization (FISH) results. A)** G-banded chromosome analysis shows a normal female karyotype. **B-D)** FISH analyses show normal hybridization with an MDS panel using probes for EGR1 (5q31, red signal) and its control probe D5S23 (5p15.2, green signal) in **B**; D7S486 (7q31, red signal) and its control probe D7Z1 (7centromere, green signal) in **C**; CEP8 (green signal) for chromosome 8 centromere and D20S108 (20q12, red signal) in **D**.](1755-8166-7-35-2){#F2}

![**5q31.2 deletion. A)** Chromosome 5 with deletion at q31.2. **B)** SNP-array results, including the weighted log2 ratio, copy number state, and allele peaks at the deleted region. **C)** Database of genomic variants showing an 896-kb deletion in the short arm of chromosome 5 within band q31.2 (position 137,821,899 to 138,718,504), including the *CTNNA1* and *HSPA9* genes.](1755-8166-7-35-3){#F3}

Of the genes deleted due to this microdeletion, two are tumor suppressor candidate genes associated with MDS/AML: *CTNNA1*, which encodes alpha-1 catenin, and *HSPA9*, which encodes heat-shock 70-KD protein 9 (mortalin) \[[@B35]\]. Deletion of *CTNNA1* was confirmed by applying BlueGnome FISH probes (RP11-114B12) (Figure [4](#F4){ref-type="fig"}). Alpha-catenins such as that encoded by *CTNNA1* are essential for the regulation of cell-cell and cell-matrix interactions in tissues \[[@B36]\]. Loss of expression of the *CTNNA1* tumor suppressor gene in hematopoietic stem cells may provide a growth advantage that contributes to human MDS/AML with 5q deletion \[[@B37]\]. Furthermore, loss of the *CTNNA1* expression has been associated with leukemia progression or transformation of MDS to AML \[[@B38]\]. The *HSPA9* gene is also located at the 5q31.2 region frequently deleted in MDS/AML, making it a candidate tumor suppressor gene; this is consistent with the biological function of its murine homologue. Human mortalin (encoded by *HSPA9*) was originally identified by its close homology to murine mortalins, which play important roles in cellular senescence \[[@B39]\]. The *HSPA9* gene is a novel negative regulator of Raf/MEK/ERK pathway that may be a potential therapeutic target \[[@B40]\].

![**FISH inverted DAPI image showing deletion of the*CTNNA1*gene using the BlueGnome FISH probe RP11-114B12 (5q31.2, red signal).** The deleted chromosome 5 is indicated by an arrow.](1755-8166-7-35-4){#F4}

The combined size of cnLOHs spanning at least 10 Mb across the genome was approximately 217.6 Mb (Figure [5](#F5){ref-type="fig"}). These were detected at the long arm of chromosomes 4, 7, and 22. The cnLOH might result from mitotic recombination or nondisjunction which leads to segmental or whole chromosomal UPD, respectively \[[@B13]\]. Acquired UPD (cnLOH) at diagnosis in our case is indicative of neoplastic evolution \[[@B12],[@B13]\]. An additional UPD was identified at 14q in the follow-up study 5 months later, confirming the genetic progression of disease (Figure [6](#F6){ref-type="fig"}).

![SNP-array results at diagnosis showing loss of heterozygosity (LOH) at the long arm of chromosomes 4, 7, and 22 as purple bars next to the corresponding chromosomes.](1755-8166-7-35-5){#F5}

![**SNP-array results at the follow-up study showing loss of heterozygosity (LOH) of chromosome 14, in addition to the LOH chromosomes 4, 7, and 22 found at initial diagnosis.** LOH is shown as purple bar next to the corresponding chromosome.](1755-8166-7-35-6){#F6}

Recent investigations have indicated that cnLOH can be responsible for homozygosity of mutations in critical genes within the region. Reduction to homozygosity as a consequence of cnLOH was initially thought to be a mechanism for only inactivation of tumor suppressor genes \[[@B14],[@B41],[@B42]\]; however, identification of cnLOH in leukemia has shown that oncogeneic mutations are also targeted \[[@B13],[@B16],[@B17]\].

Mutation analysis of 19 MDS-associated genes revealed an *ASXL1* frameshift/stop mutation (Y591\*, 41% of reads), an *EZH2* point mutation (R690H, 85%), two *RUNX1* frameshift/stop mutations (c.474dupT, 19% and c.424_425ins11bp, 7%), and two *TET2* frameshift/stop mutations (c.1510_1513delAAAA, 77% and R1465\*, 10%). These mutated genes are located on chromosomes 20, 7, 21, and 4, respectively. Recent studies have shown that *TET2* mutations are present in up to 30% of MDS/MPN cases, with mutations in *ASXL1, EZH2,* and *RUNX1* also commonly reported \[[@B43]\]. The finding of mutations in all four of these myeloid regulatory genes suggests that they play a critical role in the pathogenesis of this case and demonstrate that mutation analysis is useful in cytogenetically normal myeloid disorders \[[@B43]\].

The cnLOH affecting chromosome 7q and homozygous *EZH2* mutation have been reported in 10% of AML and MDS cases. They have been associated with a poor prognosis \[[@B9],[@B26],[@B44]\] and clonal evolution \[[@B45],[@B46]\], supporting the possible role of *EZH2* as a tumor suppressor gene for myeloid malignancies.

In contrast to the mutated *TET2* and *EZH2* genes, no LOH was found for the other two mutated genes (*RUNX1* and *ASXL1*). *RUNX1* mutations have been proposed as clinically useful biomarkers to follow disease progression from MDS to AML as well as to monitor minimal residual disease (MRD) \[[@B47]\]. Moreover, *RUNX1* mutations were demonstrated to be frequent in *de novo* AML with non-complex karyotypes and conferred an unfavorable prognosis \[[@B48]\] explained by an association with resistance to chemotherapy \[[@B49]\].

Mutations in *ASXL1* have been identified in MDS, AML, chronic myeloid leukemia, chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia \[[@B50]-[@B54]\], and act as a tumor suppressor in myeloid malignancies \[[@B50]\]. Mutations in *ASXL1*, *TET2*, and *EZH2* have been found in 41% of MDS cases in a Chinese population \[[@B44]\], similar to the data reported in patients of European decent with MDS \[[@B21],[@B23],[@B24],[@B55],[@B56]\].

Conclusion
==========

In conclusion, our study identified four large cnLOH and a microdeletion at 5q31 harboring two tumor suppressor genes (*CTNNA1* and *HSPA9*) in an MDS case with an apparently normal karyotype. The regions of cnLOH at chromosomes 4, 7, 14, and 22 confirm and extend previous studies, supporting that cnLOHs in myeloid disorders are common and nonrandom. Moreover, the presence of an additional aUPD 14q at follow up, along with persistence of the 5q31 microdeletion and all cnLOHs detected at presentation, indicates genetic progression of the disease. The deletion of tumor suppressor genes *CTNNA1* and *HSPA9*, along with mutation of candidate myeloid regulatory genes *TET2* and *EZH2*, supports the diagnosis of MDS and likely portends a poor prognosis.

This study attests to the fact that some patients with a myelodysplastic syndrome exhibiting a normal karyotype may have underlying genetic abnormalities detectable by chromosomal microarray and/or targeted mutation analyses. Further genomic and molecular studies on a series of patients with MDS may yield information on how to stratify this category of disease to seek further molecular definition.
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